The clinical trial, conducted in partnership with AbbVie, tested a combination of the drug Epkinly and Bristol Myers Squibb’s Revlimid. In patients with diffuse large B-cell lymphoma who had previously undergone at least one round of treatment, the regimen significantly extended the period of progression-free survival compared to standard care.
In section Market Quotes
Genmab Stock Rallies on Positive Lymphoma Trial Results
Shares of Genmab jumped 6% Tuesday after the Danish biotechnology firm reported that a late-stage trial for its lymphoma therapy successfully met its primary endpoint. The result offers a potential breakthrough in blood cancer treatment, positioning the company to challenge established therapies with a chemotherapy-free regimen.
Jefferies analysts noted that these findings match the efficacy benchmarks set by Roche’s Columvi and Lunsumio while providing the added benefit of a chemotherapy-free protocol. Beyond the immediate clinical success, the data lowers the risk profile for potential use as a first-line treatment. Genmab and AbbVie now plan to initiate discussions with global regulatory authorities to determine the path toward market authorization for this specific combination.
Comments (0)
No comments yet. Be the first!